Short Interest in Option Care Health, Inc. (NASDAQ:OPCH) Declines By 14.9%

Option Care Health, Inc. (NASDAQ:OPCH) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 6,150,000 shares, a decrease of 14.9% from the May 31st total of 7,230,000 shares. Currently, 3.6% of the company’s stock are short sold. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is currently 4.8 days.

Analysts Set New Price Targets

OPCH has been the topic of several research reports. Jefferies Financial Group upped their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th. Barrington Research reissued an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a research note on Wednesday, April 24th.

Institutional Investors Weigh In On Option Care Health

A number of institutional investors and hedge funds have recently bought and sold shares of OPCH. Mutual of America Capital Management LLC grew its stake in shares of Option Care Health by 63.3% in the 4th quarter. Mutual of America Capital Management LLC now owns 190,684 shares of the company’s stock worth $6,424,000 after acquiring an additional 73,938 shares in the last quarter. Westfield Capital Management Co. LP grew its position in Option Care Health by 19.6% in the 4th quarter. Westfield Capital Management Co. LP now owns 4,482,732 shares of the company’s stock worth $151,023,000 after purchasing an additional 735,344 shares in the last quarter. Principal Financial Group Inc. increased its stake in Option Care Health by 6.9% in the 4th quarter. Principal Financial Group Inc. now owns 968,233 shares of the company’s stock valued at $32,620,000 after buying an additional 62,449 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Option Care Health by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,896,392 shares of the company’s stock worth $93,698,000 after buying an additional 397,627 shares in the last quarter. Finally, HealthInvest Partners AB bought a new position in shares of Option Care Health during the 4th quarter worth approximately $1,254,000. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Stock Up 0.7 %

Shares of NASDAQ OPCH traded up $0.19 during mid-day trading on Tuesday, reaching $27.53. 317,453 shares of the company’s stock traded hands, compared to its average volume of 1,344,387. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.39. The business has a 50-day simple moving average of $29.20 and a 200 day simple moving average of $31.24. The stock has a market cap of $4.79 billion, a P/E ratio of 17.99, a PEG ratio of 1.35 and a beta of 1.24. Option Care Health has a 1-year low of $26.17 and a 1-year high of $35.74.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.10 billion. Option Care Health had a return on equity of 18.92% and a net margin of 6.15%. The company’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.21 EPS. On average, analysts expect that Option Care Health will post 1.19 EPS for the current fiscal year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.